First Eagle Investment Management LLC purchased a new position in AngioDynamics, Inc. (NASDAQ:ANGO – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 218,369 shares of the medical instruments supplier’s stock, valued at approximately $1,321,000. First Eagle Investment Management LLC owned about 0.55% of AngioDynamics as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD lifted its position in shares of AngioDynamics by 9.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 33,772 shares of the medical instruments supplier’s stock worth $199,000 after purchasing an additional 2,821 shares during the period. State Board of Administration of Florida Retirement System lifted its position in shares of AngioDynamics by 44.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 15,627 shares of the medical instruments supplier’s stock worth $92,000 after purchasing an additional 4,780 shares during the period. Quest Partners LLC purchased a new stake in shares of AngioDynamics in the 4th quarter worth about $69,000. RPO LLC purchased a new stake in shares of AngioDynamics in the 4th quarter worth about $83,000. Finally, Bank of New York Mellon Corp lifted its position in shares of AngioDynamics by 9.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 174,742 shares of the medical instruments supplier’s stock worth $1,057,000 after purchasing an additional 15,412 shares during the period. Institutional investors own 89.43% of the company’s stock.
AngioDynamics Price Performance
Shares of NASDAQ ANGO opened at $7.54 on Friday. AngioDynamics, Inc. has a 1 year low of $5.26 and a 1 year high of $8.25. The stock has a market cap of $302.01 million, a P/E ratio of -1.56 and a beta of 0.65. The firm has a 50-day moving average of $7.45 and a 200 day moving average of $6.51.
Wall Street Analysts Forecast Growth
A number of research analysts recently issued reports on the stock. Canaccord Genuity Group lowered their price target on shares of AngioDynamics from $18.00 to $13.00 and set a “buy” rating for the company in a research report on Wednesday, July 17th. HC Wainwright reissued a “buy” rating and set a $14.00 price target on shares of AngioDynamics in a research report on Friday. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $12.25.
Get Our Latest Analysis on AngioDynamics
AngioDynamics Profile
AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.
Featured Stories
- Five stocks we like better than AngioDynamics
- What is the Hang Seng index?
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- 3 Healthcare Dividend Stocks to Buy
- MarketBeat Week in Review – 9/16 – 9/20
- What to Know About Investing in Penny Stocks
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.